Vicente Anido, Chairman and Chief Executive Officer of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), will present at the 15th Annual Needham Healthcare Conference. Dr. Anido’s presentation will feature an Aerie overview and a business update. The contents of the presentation will be made available on Aerie’s website through a webcast whose replay will be accessible for 10 business days.
The clinical-stage pharmaceutical company’s focus is on the development and commercialization of first-in-class therapies for glaucoma and other diseases of the eye.
The company already has two lead product candidates. The first candidate is an IOP-lowering therapy (intra-occular pressure) whose administration is once-daily and contains novel mechanisms of action to treat patients with glaucoma and ocular hypertension. By the third quarter of the year, an NDA filing for Rhopressa (netarsudil ophthalmic solution) is expected to take place.
RoclatanTM (netarsudil/latanoprost ophthalmic solution) is the second candidate of the company’s lead products. It is currently undergoing two Phase 3 registration trials nicknamed Mercury 1 and Mercury 2.
There is a lot of optimism surrounding the two trials and a Roclatan NDA filing is expected to take place in the second half of 2017. The move could be a big boost for Aerie and will give the company more milestones for future success.
From the look of things Aerie is already succeeding somewhat in that it is in the process of laying strategies that will facilitate the building of further pipelines. Some of the strategies the company is eyeing include research collaborations with companies likeGrayBug, Inc. and Ramot at Tel Aviv University.